• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to the new (-)-1 beta -ethyl-1 alpha -hydroxymethyl-1,2, 3,4,6,7,12,12b alpha -octa-hydroindolo[2,3-a] quinolizine of the formula (I) <IMAGE> (I) and acid addition salts thereof. According to another aspect of the invention there is provided a process for the preparation of the compound of formula (I) and acid addition salts thereof by resolution of the corresponding racemic compound and optionally by subsequent hydrolysis and/or salt formation. The compound of formula (I) shows a remarkable peripheral vasodilating and antihypoxial activity. Pharmaceutical compositions comprising it as active ingredient are also within the scope of the invention.
    公开号:SU1438612A3
    申请号:SU864027292
    申请日:1986-04-18
    公开日:1988-11-15
    发明作者:Сантаи Чаба；Сабо Лайош；Калауш Дьердь；Сомбательи Жолт；Карпати Эгон；Кишш Бела；Чомор Каталин；Ласловски Иштван；Лапиш Эржебет；Спорни Ласло；Форгач Лилла；Кути Чаба；Гере Анико
    申请人:Рихтер Гедеон Ведьесети Дьяр.Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    oo 00
    O5
    to

    S
      U38612
    The invention relates to the preparation of a new optically active compound - (-) - 1/5-ethyl-o - (hydroxymethyl) -1,2 3,4,6,7,12, 2Bo-oct9-hydroindolo (2,3-a) quinolizine of the formula :
    odds (with
    f ditch ras ost pins arr

    rn:
    N N
    nssss sgnz
    or its hydrobromide having a vasodilating action and anti-hypoxic activity.
    The aim of the invention is to develop a method for producing a novel compound having valuable pharmacological properties with low toxicity.
    The invention is illustrated by the following examples.
    Example 1. (“) -1 / 5- (Acetoxy-methyl) - W-ethyl-1,2,3, 4,6, 7, J 2, 2B3-ok. Taghydroindolo (2,3-a) -quinolysin and {-) (acetoxymethyl) -1 / 3-ethyl-1,2, 3,4,6, 7,12,12 bc / -octagidroindolo (2,3-a) -quinolizin.
    2.4619g (7.54 mmol) (1) -1- (hydroxymethyl) -1-ethyl-1.2o3, 4,6,7,12,12b with -octagidroindolo (2,3-a) quinolizine dissolved in 25 ml of anhydrous acetone. To a solution heated to boiling point A solution of 1.1319 g (7.54 mmol) of D-tartaric acid, prepared with 25 ml of anhydrous acetone, was added. The mixture was allowed to crystallize at room temperature for 24-28 hours. The crystalline product precipitated out was filtered and washed with a small amount of acetone. As a result, 2, OQ g of tartrate. The salt was dissolved in 50 ml of distilled water, after which, while cooling with ice water, the solution was basified to pH 8 by the addition of a 5% sodium carbonate solution. The alkaline solution was extracted three times with dichpormethane, each time using 20 ml of the latter. The combined organic solutions were dried: over anhydrous magnesium sulphate, and then evaporated in vacuo. The oily substance obtained as a residue was crystallized from methyl alcohol. As a result, 1.20 g (97.4%) of the title (+) - compound in crystalline
    five
    0
    form. M.p. 122-123 ° С, С. Р +38,7 (, dichloromethane) о
    The mother liquor left after separation by filtration of the tartrate salt was evaporated in vacuo. 1.65 g of a foamy solid was obtained as a residue. After its treatment by the described method, the product was obtained, which was crystallized from methyl alcohol. As a result, 1.0 g (81.2%) of the title compound (-) - was obtained in the form of a crystalline substance. M.p. 1225 123 C, -37, (, dichloromethane). ;
    P r and m er. 2. (+) - L-Ethyl- (oxymethyl) -, 2,3,4,6,7,12,12L /} - octa-hydroindolo (2,3-a) -quinolizin and (-) 0 lji-ethyl-Y- (hydroxymethyl) -, 2,3,4,56,7, 1 2 ,, 1 2b o (-octagidroindolo (2, .3-a) -quinolizin.
    a.1.95 g (5997 mmol) obtained in example 1 - () - 1 / 1- (acetyloxymethyl) - tyl-l, 2,3,4,6,7, J2, J2b / 3-octahydroindolo ( 2,3-a) -quinolysin was dissolved in 100 ml of anhydrous methyl alcohol heated to boiling point. 0.05 g (0.92 mmol) of sodium methoxide was added to the solution, after which the mixture was heated at reflux for 30 minutes. After cooling, the reaction mixture was poured into
    5 300 ml of distilled water. The precipitated white crystalline solid was filtered and washed with cold water. As a result, 1.65 g (97.6%) of the title (+) - compound was listed. So. pl, 220-221 C, C "J.jj-ShO, 4 ° (, dimethylformamide),
    b.From obtained in Example 1 (-). 1 (acetyl oxymethyl) -1p-ethyl-1,2,3.45 6,7,12,12Lo of octahydroindolo (2,3-a) -quinolysin was obtained as described in paragraph a and the method in the title of the levorotatory compound. Yield 1.60 g (94.2%) of crystalline substance, mp 222-221 s, U. C -108.0 ° (dimethylformamide).
    The obtained substance was dissolved in a ten-fold amount of acetone, the solution was heated at the boiling point and mixed with a 48% aqueous solution of hydrobromic acid, and the hydrobromide of the title compound was obtained. M.p. 280-282 0 (after recrystallized 3U
    methanol alcohol t, pl. 285- 28 7 C).
    The vasodilatory effect of the new levorotatory trans-compound of formula (I) was investigated on anesthetized dogs. In Arteria femoralis and Arteria carotis interna, animals were injected with electromagnetic flow measuring heads and the amount of blood flowing through the vessels was measured. Using a pressure-sensitive Statham element, which was placed in a polyethylene cannula inserted into the artery, the mean arterial pressure was measured. The number of beats per minute was determined using a counter-frequency meter from the pulsatory blood pressure component. All measured values were continuously recorded with the help of an am-recorder
    In the study of the effect, the corresponding right-handed transboundary compound was used as well as the (±)-racemate of both transunited compounds,
    The levorotatory transcompound of formula (I) at the applied dose did not affect the blood circulation parameters studied, namely the number of pulse beats and blood flow in A.carotis. In the case of all three investigated substances, the blood pressure temporarily decreased to a small extent. This effect was most strongly observed (with 20%) in the case of the use of the racemic compound, to a lesser degree (with 6%) in the case of (+) - isomer and in 7710% in the case of (-) - isomer. The pharmacological effect of the invention The levorotatory transsocial connection showed an increase in blood flow in Arteria femoralis. Therefore, for comparison, the effect of pentoxifylline, which differs in structure from that of the compound of the invention but has been successfully used as a means for dilation of limb vessels, was also investigated.
    The effect of each compound was studied on several (p) animals. From the nojTy4eHHbix results, the average value was calculated
    Table 1 shows the effect of various compounds on the blood flow in Arteria femoralis when administered intravenously.
    2
    Table 1 shows that the vasodilatory effect of the inventive new trans - (-) - stereoisomer exceeds the action of pentoxifylline, the action of (+) - stereoisomer is more than a hundred times, and the action of the racemate is about thirty times.
    In addition, the well-known racemate and right-orbiting trans-compound are most active at doses of 1.0 mg / kg, and the levorotating trans-compound according to the invention is most active at a very small dose (0.03 mg / kg). If the racemate and dextrorotatory compound is used in the same small dose, the right rotatory compound has no effect at all, and the action of the racemate is approximately one sixth of the effect of the compound corresponding to the invention and lasts only 1 minute. min
    The antihypoxic activity of a new levorotatory compound was investigated for non-narcotizing under hypoxic conditions,
    Five male mice were placed in a 3 l glass cylinder. The glass vessel was continuously purged with a gas mixture of 96% nitrogen and 4% oxygen. The time was measured between the time of placement in the cylinder and the death of animals. The average duration of the rehash of untreated control animals was 6.2 min, and those that were twice as long after the time (12, And the min were still alive, were considered protected, in each case 20 animals per 30 minutes before the start of the experiment, substances were administered intraperitoneally for comparison at a dose of 50 mg / kg, and the compound according to the invention at a dose of 25 mg / kg. The time (average value) that passed before the death of treated animals was compared with the average duration of survival of the treated animals. s, with the difference expressed as a percentage.
    The antihypoxic activity of the new levorotatory transcompound according to the invention was compared with the activity of the corresponding dextrorot stereoisomer and with the activity of the racemate consisting of both isomers.
    51
    The results of the experiment are given in table 2,
    From the data presented in Table 2, it follows that the new levogyrate stericisomer corresponding to the invention, in contrast to the corresponding programal stereoisomer, and also the racemate, exhibits significant antihypoxic activity, i.e. significantly increases the resistance of tissues and organs of the body against hypoxia already at low doses. When the diseases of the blood vessels and organs associated with the blood vessels are significantly deteriorated, hypoxia occurs, as a result of which the tissue dies off, therefore, the vasodilatory effect of increasing the resistance of the cells against hypoxia is favorable from the point of view of therapeutic indications.
    The well-known dextrorotomy transcription 1 and the racemate, even in high doses, do not possess antihypoxic activity, namely, the 10% frequency of protection is insignificant (in untreated animals, protection is in this area).
    The toxicity of Compound I is 150.3 mg / kg P.O. for smaller.
    权利要求:
    Claims (2)
    [1]
    Invention Formula
    j. Way to crawl. () -l / -tsшl- | and- (hydroxymethyl) -1,2,3,, 7,12,12 Lo I of octahydroindolo (2,3-a) -quinolizin I of formula I
    H
    to n ..L.HO-CH C HS
    or its hydrobromide, characterized in that the mixture is -W-3THfl-lp- (acetyloxymethyl) -, 2,3,4,6,7,12,12 «" (-octagidro-iczo (2,3-a) -quinolizine of the formula Na and 1-ethyl-1o - (acetyloxymethyl) -1,2,3,4,6,7,12,2L (-octahydro-roindolo (2,3-a) -quinolizine formul II b
    II N N
    СНзС-0-СН2 СгН5 СНзС-0-СН2 Н5
    which are present in the mixture in a 1: 1 ratio, are divided into optically active isomers, the resulting intermediate compound of formula III
    СНзС-0-СН2 С2Н5
    hydrolyzed and the desired product is liberated or in the form of hydrobromide,
    [2]
    2. The POP.1 method, characterized in that B-tartaric acid is used to separate the mixture of the compounds of In and lib into optically active isomers.
    T a b l and c a. one
    Known (+) - 1 (hydroxymethyl) produced (German patent
     2520131, compound II
    with R N)
    New (+) - 1- (hydroxymethyl) -derivative
    New (-) - 1- (hydroxymethyl) is a derivative of formula I (dose 2.5 mg / kg)
    The known (+) - 1- (acetoxime-
    til) - derivative (patent of Germany
    No. 2520131, compound II with
    R CH)
    (+) -1- (Acetoxymethyl) derivative
    (-) - 1- (Acetoxymethyl)-derivative (III) with R - CHj
    Known (+) - 1- (propionyl- v-oxymethyl) -derivative (German patent 2520 131, compound He)
    table 2
    ten
    类似技术:
    公开号 | 公开日 | 专利标题
    KR850000301B1|1985-03-18|Process for the preparation of phenyethanol amines
    RU2089550C1|1997-09-10|1,4-benzothiazepine derivative
    DE19834045A1|2000-02-03| -1- | -1H-pyrazolo [3,4-b] pyridine
    SU1402259A3|1988-06-07|Method of producing substituted 2-phenylhexahydro-1,2,4-triazine-3,5-diones
    SU1438612A3|1988-11-15|Method of producing |-1 beta-ethyl-1 alpha-|-1,2,3,4,6,6,7,12, 12 b alpha-octahydroindolo |-quinolisin or hydrobromide thereof
    US4560686A|1985-12-24|Method for treating circulatory diseases by using |piperazine derivatives
    US4528289A|1985-07-09|Corynantheine derivates, processes for their preparation, and their use
    SU1635899A3|1991-03-15|Process for preparing 3-[|methyl]-2- oxybenzene methanols
    EP0076755B1|1988-01-13|Acylamino-4-aza-1-adamantanes, process for their preparation and their therapeutic use
    US3057780A|1962-10-09|Method for treatment of mental disease
    US4405636A|1983-09-20|N-|2-methoxy-4-amino-5-methylsufamoyl benzamide, its method of preparation and its use as a medicament
    US4034103A|1977-07-05|Aralkylamino sulfones having spasmolytic activities
    JP3065506B2|2000-07-17|Pyrazolidine derivative and radical scavenger, cerebral infarction inhibitor, cerebral edema inhibitor
    US4218479A|1980-08-19|Novel benzylalcohols and pharmaceutical compositions and use thereof
    DE3704879A1|1988-08-25|PYRIDAZINE DERIVATIVES
    KR880001079B1|1988-06-22|Process for preparation of|-1 beta-ethyl-1 alpha-hydroxymethyl-1,2,3,4,6,7,12,12b alpha-octahydroindolo|quinolizine
    SU1205767A3|1986-01-15|Method of producing internal salts of naphthalenylthiazole derivatives
    CS240982B2|1986-03-13|Production method of pyrrolidine derivatives
    AT376981B|1985-01-25|METHOD FOR PRODUCING NEW PYRIDO- | PYRIMIDINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THEIR SOLVATES, STEREOISOMERS AND TAUTOMERS
    EP0340030A2|1989-11-02|Triazine derivatives
    US4056535A|1977-11-01|N-substituted 3-aminopyrrolidines
    DE2627933A1|1977-01-13|DERIVATIVES OF 5-AMINO-1,2,4-OXADIAZOLEN, THE METHOD FOR THEIR MANUFACTURING AND THE MEDICINAL PREPARATIONS CONTAINING THEM
    CS221846B2|1983-04-29|Method of making the ethanolamine derivatives
    US4271194A|1981-06-02|Sedative compositions containing |-acetamidoxime and its addition salts and method of use
    FR2543954A1|1984-10-12|4-Acylamino-1-azaadamantanes, process for their preparation and application in therapeutics
    同族专利:
    公开号 | 公开日
    DK159780B|1990-12-03|
    CS286386A2|1990-09-12|
    CN86102479A|1986-10-22|
    IE59199B1|1994-01-26|
    NZ215879A|1989-04-26|
    GR861027B|1986-08-12|
    AU5638386A|1986-10-23|
    NL8600976A|1986-11-17|
    IE861033L|1986-10-19|
    DE3613180A1|1986-10-23|
    IT8620136D0|1986-04-18|
    CA1299574C|1992-04-28|
    ES8706152A1|1987-06-01|
    FI861641A0|1986-04-18|
    ES554143A0|1987-06-01|
    DK179786A|1986-10-20|
    DE3613180C2|1995-10-19|
    IL78538A|1989-10-31|
    FI83870C|1991-09-10|
    CS274276B2|1991-04-11|
    PT82424B|1988-03-03|
    US4806545A|1989-02-21|
    FR2580649B1|1991-03-29|
    NO167143C|1991-10-09|
    CH668262A5|1988-12-15|
    DK179786D0|1986-04-18|
    BE904588A|1986-10-14|
    AU591896B2|1989-12-21|
    ZA862941B|1986-12-30|
    NO861539L|1986-10-20|
    GB8609533D0|1986-05-21|
    GB2174701A|1986-11-12|
    DK159780C|1991-04-22|
    GB2174701B|1989-02-15|
    HU194221B|1988-01-28|
    IL78538D0|1986-08-31|
    IN162810B|1988-07-09|
    DD244556A5|1987-04-08|
    EG18059A|1991-06-30|
    LU86397A1|1986-09-02|
    BG60433B2|1995-03-31|
    NO167143B|1991-07-01|
    SE8601799L|1986-10-20|
    PH25316A|1991-04-30|
    AT390954B|1990-07-25|
    YU62486A|1988-06-30|
    FI83870B|1991-05-31|
    SE8601799D0|1986-04-18|
    ATA102986A|1990-01-15|
    PT82424A|1986-05-01|
    IT1204306B|1989-03-01|
    SE460196B|1989-09-18|
    CN1023560C|1994-01-19|
    JPH072637B2|1995-01-18|
    FI861641A|1986-10-20|
    YU44286B|1990-04-30|
    HUT40433A|1986-12-28|
    AR240699A1|1990-09-28|
    JPS61249986A|1986-11-07|
    FR2580649A1|1986-10-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1499546A|1974-05-07|1978-02-01|Richter Gedeon Vegyeszet|Indolo-quinolizidine derivatives and a process for the preparation thereof|
    HU170495B|1974-05-07|1977-06-28|
    HU194220B|1985-04-19|1988-01-28|Richter Gedeon Vegyeszet|Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof|
    HU195214B|1985-04-19|1988-04-28|Richter Gedeon Vegyeszet|Process for producing 12b-substituted-1--octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds|HU191454B|1984-10-05|1987-02-27|Richter Gedeon Vegyeszeti Gyar Rt.,Hu|Process for producing amides of oktahydro-indolo/2,3-a/quinolyzin-1-yl-alkanecarboxylic acids and pharmaceutically acceptable acid additional salts thereof|
    HU194220B|1985-04-19|1988-01-28|Richter Gedeon Vegyeszet|Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof|
    HU195214B|1985-04-19|1988-04-28|Richter Gedeon Vegyeszet|Process for producing 12b-substituted-1--octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds|
    HU207070B|1990-10-31|1993-03-01|Richter Gedeon Vegyeszet|Process for producing 1beta-ethyl-1alpha-hydroxymethyl-1,2,3,4,6,712,12balpha-octahydroindolo quinolizine|
    DE19821039A1|1998-05-11|1999-11-18|Bayer Ag|Production of -8-benzyl-2,8-diazabicyclononane useful as intermediate for antibiotic moxifloxacin|
    EP1490361B1|2002-04-03|2007-10-03|Orion Corporation|Polycyclic compounds as potent alpha2-adrenoceptor antagonists|
    AU2003235931A1|2002-05-13|2003-11-11|Takata Seiyaku Co., Ltd.|Vintoperol-containing medicinal composition for transdermal administration|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU851519A|HU194221B|1985-04-19|1985-04-19|Process for preparing novel octahydro-indolo/2,3-a/quinoline derivative and pharmaceutical comprising this compound|LV930045A| LV5260A3|1985-04-19|1993-01-18| - 1 beta-ethyl-1alpha--1,2,3,4,6,7,12,12b alpha-octa-hydroxyindoloquinolizine or its hydrobromide yield|
    LTRP856A| LT2201B|1985-04-19|1993-08-13| - 1BETA-ETHYL-1 ALPHA--1,2,3,4,6,7,12, BETA ALPHA-OKTAHYDRROINDOLOCHINOLIZIN OR HYDROBROMIDES|
    [返回顶部]